GLP-1 vs Ozempic: Clinical Differences & Similarities

Last reviewed: June 3, 2026

Last updated: June 3, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

GLP-1 and Ozempic are not the same. GLP-1 is a hormone class and medication category; Ozempic is one branded semaglutide injection marketed for type 2 diabetes. Semaglutide is a synthetic GLP-1 receptor agonist—meaning it mimics the natural hormone GLP-1 but is not identical to it.

This distinction matters because the GLP-1 class includes multiple formulations (semaglutide, tirzepatide, retatrutide) available in branded and compounded forms, each with different dosing schedules, routes, and accessibility profiles. Understanding these differences—along with how your genetic predispositions influence peptide pathway response—can help guide a more personalized conversation with your healthcare provider.

GLP-1 as a Hormone Class Versus Ozempic as a Brand Name

GLP-1 (glucagon-like peptide-1) is an incretin hormone naturally produced in the intestines. It regulates blood glucose, slows gastric emptying, and signals fullness to the brain. GLP-1 receptor agonists are synthetic medications that activate the same receptor, mimicking these effects. Ozempic is Novo Nordisk's branded semaglutide injection.

Other GLP-1 receptor agonists include Wegovy (higher-dose semaglutide for weight management), Victoza (lower-dose semaglutide), Saxenda (liraglutide), and tirzepatide (Mounjaro/Zepbound). Each has distinct pharmacokinetics, dosing intervals, and regulatory approvals. Compounded semaglutide and tirzepatide are also available through licensed pharmacies, offering alternative formulations at different price points.

How Semaglutide (Ozempic's Active Ingredient) Works in the GLP-1 Class

Semaglutide binds to GLP-1 receptors on pancreatic beta cells, intestinal L-cells, and the hypothalamus. This triggers insulin secretion when blood glucose is elevated, delays gastric emptying, reduces appetite signaling, and increases satiety. These mechanisms support glucose control and weight loss in many patients.

Below is a comparison of semaglutide's properties within the broader GLP-1 class, showing how it differs from other GLP-1 and GLP-1/GIP receptor agonists in terms of structure, receptor selectivity, and approved indications.

Characteristic	Semaglutide (Ozempic/Wegovy)	Tirzepatide (Mounjaro/Zepbound)	Liraglutide (Saxenda/Victoza)
Receptor Target	GLP-1 only	GLP-1 + GIP dual agonist	GLP-1 only
Dosing Schedule	Once weekly injection	Once weekly injection	Daily injection
Half-life	~7 days	~5 days	~13 hours
FDA Indications	Type 2 diabetes & weight loss (Wegovy)	Type 2 diabetes & weight loss (Zepbound)	Type 2 diabetes & weight loss (Saxenda)
Available Forms	Branded injections & compounded semaglutide	Branded injections & compounded tirzepatide	Branded injection only

Ozempic Versus Compounded Semaglutide: Access, Pricing, and Clinical Considerations

Ozempic is a branded, FDA-approved injectable semaglutide indicated for type 2 diabetes. It requires a prescription and is subject to insurance coverage decisions and cost-sharing. Compounded semaglutide is formulated by licensed 503A pharmacies and offers a more affordable alternative without insurance barriers, though it is not FDA-approved as a finished pharmaceutical product.

PlexusDx offers compounded semaglutide injections at $189/mo month-to-month, or from $149/mo on the 6-month plan across flexible commitment tiers—a significant cost reduction compared to many branded GLP-1 therapies. Patients should discuss both options with their healthcare provider, considering their medical history, insurance coverage, and preference for branded versus compounded formulations. Neither guarantees specific outcomes; individual response varies.

Genetic Predispositions and Individual Response Variation to GLP-1 Therapy

Not all patients respond equally to GLP-1 receptor agonists. Natural variation in GIPR, FTO, and MC4R gene variants influences how individuals metabolize these medications and achieve weight loss or glucose control. A patient with favorable GLP1R genetic predispositions, for example, may show stronger appetite suppression than someone with genetic variants linked to reduced GLP-1 receptor sensitivity.

PlexusDx's Precision Peptide Genetic Test analyzes key variants in these peptide pathways to reveal predispositions that may inform treatment selection and titration strategy. This information should be interpreted with a qualified healthcare provider and does not predict exact medication response. Combined with clinical assessment, biomarker insights can support a more targeted conversation about which GLP-1 formulation may align best with your physiology.

How PlexusDx Supports a More Personalized Approach

PlexusDx clarifies that GLP-1 is a therapeutic class with multiple formulations—branded (Ozempic, Wegovy, Mounjaro) and compounded (semaglutide, tirzepatide). Understanding these distinctions helps patients evaluate which option suits their clinical needs, budget, and preference. The Precision Peptide Genetic Test may help provide context on how genetic predispositions in GIPR, FTO, and MC4R pathways relate to individual GLP-1 response variability, though this information should always be interpreted with a qualified healthcare provider.

The Precision Peptide Genetic Test reveals predispositions in four key peptide pathway variants: GLP1R rs6923761 (GLP-1 receptor sensitivity), GIPR rs1800437 (GLP-1/GIP pathway response), FTO rs9939609 (metabolic predisposition), and MC4R rs17782313 (appetite regulation). These predispositions do not predict exact medication response but may help explain why some individuals experience stronger or weaker responses to GLP-1 therapy. This test is available for $298.

When evaluating GLP-1 options—whether branded Ozempic, generic semaglutide, or compounded formulations—consider discussing your genetic predispositions with your provider. This conversation can support more informed decisions about dose titration, expected response timeline, and whether a dual-agonist approach (like tirzepatide or GLP-Squared) might align better with your peptide pathway profile. PlexusDx providers can integrate genetic insights into personalized treatment planning.

How Your Genetics Relate to GLP-1 Pathways

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, FTO rs9939609, and MC4R rs17782313 — relate to the biological pathways these medications act on. These are pathway-level associations only and do not predict how much weight you will lose or how you will respond to any specific medication. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights so you and your provider can see how your genes relate to these pathways. It does not recommend, prescribe, or determine which medication, dose, or peptide is right for you. The PlexusDx Precision Peptide Genetic Test ($298) gives you and your provider pathway-level genetic context to support a more personalized conversation. Genetics is a guide, not a guarantee.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers seven prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Semaglutide Oral is $289/mo month-to-month, or from $249/mo on the 6-month plan. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test ($298) to personalize your protocol from day one.

Frequently Asked Questions

Is Ozempic a type of GLP-1 or the other way around?

Ozempic sits inside the category. The article explains that GLP-1 names both a natural hormone and a class of medications that act on its receptor, while Ozempic is one specific branded semaglutide injection marketed for type 2 diabetes. Treating the brand name as a synonym for the whole class is the confusion the article sets out to fix.

Is semaglutide identical to the natural GLP-1 hormone?

No. The article describes semaglutide as a synthetic GLP-1 receptor agonist, meaning it mimics the natural hormone and activates the same receptor without being the same molecule. The natural hormone is an incretin produced in the intestines that regulates blood glucose, slows gastric emptying and signals fullness. The medication amplifies those signals rather than replacing them.

Why does the same semaglutide molecule appear under two different brand names?

Because the branded products differ in dose and approved indication rather than in active ingredient. The article describes Wegovy as higher-dose semaglutide for weight management, while Ozempic is the branded semaglutide injection marketed for type 2 diabetes. Same molecule, different regulatory approvals and different labeled use.

Does half-life explain weekly versus daily dosing in this class?

It maps closely. The article's comparison table gives semaglutide a half-life of about seven days with once-weekly injection, tirzepatide about five days also weekly, and liraglutide roughly thirteen hours with daily injection. A molecule that clears in hours cannot hold a steady signal for a week. That is why dosing intervals differ so sharply within one drug class.

Which medications in this class are available only as branded injections?

The article's table lists liraglutide as branded injection only, while both semaglutide and tirzepatide appear in branded and compounded forms. That distinction matters mainly for access and cost, since compounded preparations sit outside the FDA approval process for finished products. Which route is available to you depends on your prescriber and the dispensing pharmacy.

Related Reading

• Maximus Glp 1
• Found Glp 1
• Orderly Meds Glp 1
• Henry Meds Glp 1

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.